Mobile website
Clinical Research
Co-expressions of CD133 and EGFRvⅢ in gliomas and their clinical significance
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To observe the co-expressions of human glioma tumor stem cell marker (CD133) and epidermal growth factor receptor variant Ⅲ (EGFRvⅢ) in the glioma tissues and their clinical significance. Methods: Forty glioma samples (17 with grade Ⅱ, 12 with grade Ⅲ, 11 with grade IV) were obtained from patients with glioma (who had been diagnosed in the People’s Hospital, Zhengzhou University, from Jan. 2011 to Jun. 2011) receiving surgery. The percentages of CD133+, EGFRvⅢ+ and CD133+/EGFRvⅢ+ cells in the glioma tissues in different grades were analyzed by flow cytometry and the clinical features were compared. Results: The expression of CD133 and EGFRvⅢ in human glioma increased gradually with the pathologic grade of glioma tissue. The double positive CD133+/EGFRvⅢ+ cells were found in the glioma tissues of different grades. The percentage of CD133+/EGFRvⅢ+ cells was between （4.75±126)% to (18.26±3.45)% in different grades of gliomas, with the percentages of CD133+/EGFRvⅢ+ cells in grade Ⅲ and Ⅳ being higher significantly than that in grade Ⅱ (P<0.05). CD133+/EGFRvⅢ+ cells exerted much more influence than did cells expressing CD133+ or EGFRvⅢ+ on survival time of the gliomas patients, and the median survival time of the patients with double positive CD133+/EGFRvⅢ+ was shorter.Conclusion: The co-expressions of CD133 and EGFRvⅢ exist in human gliomas, which are related with the degree of malignant glioma and the survival rate. Our study provides a new potential target for the treatment of glioma.
Keywords:
Project Supported:
Project supported by the National Natural Science Foundation of China (No. 81172415)
Clc Number:
